|
|
32. The efficacy
of 5% minoxidil versus combined topical agent of 5% minoxidil and 0.01%
tretinoin
on male pattern hair loss: a randomised comparative clinical trial. Topical minoxidil 5% solution has been widely used to stimulate new hair growth
and to help stop the hair loss successfully in men with male pattern hair loss
(MPHL). Nevertheless, it is not easy for the patients to keep applying the
solution twice a day regularly.
The purpose of this 18-week, double-blind, randomized study is to compare the
efficacy and safety of the treatment of combined solution of 5% minoxidil and
0.01% tretinoin once a day with conventional topical 5% minoxidil therapy applying
twice a day in the treatment of MPHL.
A total of 29 male patients (25-50 years old, 39.7¡¾4.5) with
MPHL (Hamilton type III to V) were randomly assigned to apply 5% minoxidil
twice daily or the combined agent once a day at night with using vehicle placebo
in the morning.
The efficacy parameters were 1) changes in total hair count, mean hair thickness
and linear growth rate measured by phototrichogram and 2) the patient and investigator¡¯s
subjective assessment of change in scalp coverage.
After 18-week therapy, significant increases in the all macrophotographic variables
of total hair count, mean hair diameter and linear growth rate were shown in
both treatment groups. Moreover, the 5% minoxidil and the combined agent groups
also demonstrated similar improvement in the subjective global assessment by
patient and investigator. There was no statistically significant difference
between either treatment groups. The occurrence of side effects like pruritus
or local irritation was similar in 5% minoxidil group (5 of 14 subjects) and
the combined agent group (5 of 15 subjects).
In conclusion, the efficacy and safety of combined 5% minoxidil and 0.01% tretinoin
once-daily treatment would be equivalent to the conventional 5% minoxidil twice-a-day
therapy for treatment of MPHL. |
|||
|
|
|||